HK Innoen "New GERD Drug K-CAB Launched in Singapore"

Partner-Hosted Launch Symposium Held
Expansion Completed in 35 Countries

HK Innoen's potassium-competitive acid blocker (P-CAB) class gastroesophageal reflux disease (GERD) new drug 'K-CAB' has been launched in Singapore.

Professor Barnes Juicy Gawali from Washington University School of Medicine is giving a lecture to Singaporean medical staff at the Singapore K-CAP Launch Symposium.
[Photo by HK Innoen]

HK Innoen announced on the 4th that it held a symposium to commemorate the launch of the GERD new drug K-CAB (active ingredient: Tegoprazan) at the Conrad Centennial Hotel in Singapore on the 31st of last month.

The symposium, held for local gastroenterology specialists, was hosted by the local partner UITC. Professors Gawali from the Department of Gastroenterology at Barnes-Jewish Hospital, Washington University School of Medicine, and Jeong Hoon-yong from the Department of Gastroenterology at Seoul Asan Medical Center, who are authorities in gastroenterology from various countries, participated as speakers to share the latest insights on K-CAB.

Professor Gawali gave a lecture on the key advantages of K-CAB based on major clinical trials. He emphasized that K-CAB has a faster onset of action compared to other drugs in the same P-CAB class and has secured safety in terms of liver toxicity, highlighting the excellence and safety of K-CAB.

Professor Jeong Hoon-yong presented the prescription experience of K-CAB in Korea. He introduced several cases where the limitations of proton pump inhibitor (PPI) class products were overcome with K-CAB. He said, "With the advent of K-CAB, better treatment options have been provided to patients with gastroesophageal reflux disease."

K-CAB was approved by local authorities in Singapore in February. The product name was set the same as in Korea. HK Innoen exports finished products to the local partner UITC, which is responsible for local sales and marketing.

So far, K-CAB has entered a total of 35 countries overseas in the form of technology or finished product exports. Among them, six countries including China, Mongolia, the Philippines, Mexico, Indonesia, and Singapore have completed local launches. K-CAB is preparing for launch in Peru, which was approved in July, and is undergoing approval procedures in Southeast Asian and Latin American countries. In the major market of the United States, the local partner Sevela is conducting phase 3 clinical trials through technology export.

Kwok Dal-won, CEO of HK Innoen, said, "The average annual growth rate of the Singapore pharmaceutical market over the past three years is 11%, making it one of the fastest-growing countries among major Southeast Asian countries," and added, "We will continue close cooperation with local partners to ensure the successful overseas approval and launch of K-CAB."

K-CAB is a P-CAB class treatment for gastroesophageal reflux disease. It is characterized by a rapid onset of effect within 30 minutes after administration and securing efficacy and safety even with long-term use up to six months. Last year, it recorded over 130 billion KRW in outpatient prescription performance domestically and has maintained the number one position in the domestic peptic ulcer drug market since its launch in 2019.

Professor Jeong Hun-yong of Seoul Asan Medical Center is giving a lecture to Singaporean medical staff at the K-CAB Launch Symposium in Singapore.
[Photo by HK Innoen]

This content was produced with the assistance of AI translation services.